Quest Diagnostics Inc vs NRG Energy Inc — how do they compare? Quest Diagnostics Inc trades at $237.6 (market cap $26.21B), while NRG Energy Inc trades at $121.09 (market cap $24.83B). The key difference: Quest Diagnostics Inc and NRG Energy Inc are close in size by market cap, and NRG Energy Inc pays the higher dividend (1.61%). Which is the better fit depends on your goals.
| DGX | NRG | |
|---|---|---|
Market Cap | $26.21B | $24.83B |
Sector | Health | Utilities |
52-Week High | $238.50 | $184.03 |
52-Week Low | $173.49 | $117.04 |
Enterprise Value | $31.97B | $48.79B |
Dividend Yield | 1.45% | 1.61% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
NRG Energy trades at $120.97, up 1.73% today, with a bearish technical signal despite oversold RSI levels near support at $119. The company reported Q2 2026 EPS of $1.49, missing estimates of $1.69, but revenue grew 11% year-over-year, driven by cost controls and a strategic 1.2 GW Texas data-center power project. Fundamentals show a P/E of 30.76 and ROE of 26.77%, though net margin is thin at 2.56%.
Outlook is mixed: analyst consensus is bullish with a $207.83 price target (69% buy ratings), citing growth from data-center demand, but risks include rising interest costs, high leverage (debt-to-assets at 56.42% in 2025), and earnings misses. The stock offers a 1.6% dividend yield, but investors face volatility from execution risks in expansion plans.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →